Clinical Trials · NCT01923649

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

CompletedPhase 2Lanreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment
24
Start date
Apr 2008
Locations
3 sites, Belgium
Primary endpoint
Change from Baseline Total Dumping score after treatment with Somatuline 90 mg and after placebo.
View Lanreotide compound reference